ArticleBMC ophthalmology2026
Effects of anti-VEGF therapy on choroidal thickness in eyes with diabetic macular edema.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundDiabetic macular edema (DME) is a leading cause of visual impairment in working-age adults. Although anti-vascular endothelial growth factor (VEGF) therapy is the standard treatment for DME, its effects on choroidal structure remain incompletely characterized. This study aimed to evaluate changes in subfoveal choroidal thickness (SFCT) following intravitreal Conbercept injection in eyes with center-involved DME.
methodsIn this prospective study, 40 patients (51 eyes) with center-involved DME were enrolled between August 2019 and November 2022. Based on diabetic retinopathy severity, eyes were classified into non-proliferative DR with macular edema (NPDR-ME, n = 36) and proliferative DR with macular edema (PDR-ME, n = 15) groups. All eyes received intravitreal Conbercept (0.5 mg) injections. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and SFCT were measured using spectral-domain optical coherence tomography at baseline and at 1, 3, and 6 months post-treatment. Repeated measures ANOVA and Spearman correlation analyses were performed.To account for the correlation between paired eyes from patients with bilateral involvement, data were analyzed using generalized estimating equations (GEE).
resultsAt 6 months post-treatment, significant improvements were observed in logMAR BCVA (0.61 ± 0.25 to 0.33 ± 0.23, P < 0.001) and CMT (466.25 ± 129.85 to 279.41 ± 72.47 μm, P < 0.001). SFCT decreased progressively from 379.65 ± 60.59 μm at baseline to 304.63 ± 53.92 μm at 6 months (P < 0.001). No significant differences in SFCT were observed between NPDR-ME and PDR-ME groups at any time point (P > 0.05). BCVA at 6 months correlated significantly with baseline and post-treatment BCVA and CMT (P < 0.05) but not with SFCT at any time point (P > 0.05).
conclusionIntravitreal Conbercept significantly reduces subfoveal choroidal thickness in DME eyes, accompanied by improved visual acuity and reduced macular edema. The lack of correlation between SFCT changes and visual outcomes suggests that choroidal thickness may not directly reflect functional improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.